Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New AI reads CT scans to predict which esophageal cancers vanish after treatment

NCT ID NCT07181850

Diagnosis Sponsor: Nanjing Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether a computer model could predict if esophageal cancer completely disappears after chemo-immunotherapy. Researchers reviewed medical records and CT scans from 363 patients who received standard treatment before surgery. The AI combined clinical data, radiomics, and deep learning to predict which patients had no cancer left at surgery. If validated, this tool could help personalize treatment and avoid unnecessary surgeries.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
camrelizumab with paclitaxel and cisplatin or carboplatin
What this could lead to
If successful, this AI tool could help doctors quickly identify which patients benefit from chemo-immunotherapy before surgery, avoiding unnecessary treatments for non-responders.
What could go wrong
This is a retrospective observational study, not a controlled trial. The AI model needs prospective validation and may not work in different hospitals or populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

363 people

The number who actually took part.

Started

Jan 2019

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with biopsy-confirmed ESCC treated at three participating centers in China. Patients received standard neoadjuvant chemo-immunotherapy (e.g., camrelizumab with paclitaxel and cisplatin or carboplatin), had pre-treatment venous-phase chest CT within 14 days, and underwent R0 resection 6-8 weeks post-therapy. pCR status was determined from surgical pathology. Sites include: The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University; Nanjing Medical University Affiliated Cancer Hospital \& Jiangsu Cancer Hospital \& Jiangsu Institute of Cancer Research; and Nanjing Drum Tower Hospital.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Biopsy-confirmed esophageal squamous cell carcinoma (ESCC). Locally advanced disease per AJCC 8th ed. (cT1N1-T3N0-3M0) on contrast-enhanced CT. Completed standardized neoadjuvant chemo-immunotherapy (e.g., paclitaxel + cisplatin/carboplatin with camrelizumab every 2-3 weeks) prior to surgery. High-quality venous-phase chest CT (slice thickness ≤5 mm) obtained within 14 days before therapy start. Underwent R0 resection 6-8 weeks after therapy. Availability of a definitive postoperative pathology report to ascertain pCR status. Exclusion Criteria: Non-squamous histology; distant metastasis (M1); synchronous malignancies. Inadequate imaging quality (no venous phase, slice thickness \>5 mm, severe artifacts, or incomplete tumor visualization). Did not complete the full treatment course or had missing endpoints (e.g., no pathological response record or lost to follow-up).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Esophageal squamous cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Esophageal squamous cell carcinoma Pathological complete response

Contacts and locations

Locations

  • The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University

    Huai'an, Jiangsu, 223000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.